Trial Information
Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)
Inclusion Criteria:
- Burkitt's leukemia or Burkitt's lymphoma or primary mediastinal large B-cell lymphoma
or B-precursor lymphoblastic lymphoma or large cell anaplastic lymphoma
- Age > 15 years
- Written informed consent
Exclusion Criteria:
- Serious secondary diseases, including psychiatric conditions, under which the
required therapy compliance is not to be expected
- HIV infection
- Secondary lymphoma following prior chemotherapy/radiotherapy or active second
malignancy
- Known severe allergy to foreign proteins
- Pre-treatment other than 1 cycle CHOP or similar; < 1 week of another chemotherapy.
- Pregnancy or nursing
- Participation in other studies that interfere with study therapy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Remission rate
Principal Investigator
Dieter Hoelzer, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Frankfurt, Medical Dept. II
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
GMALL05
NCT ID:
NCT00199082
Start Date:
July 2002
Completion Date:
Related Keywords:
- Burkitt's Lymphoma
- Burkitt's Leukemia
- Mediastinal Neoplasms
- Lymphoblastic Lymphoma
- Large Cell Anaplastic Lymphoma
- High-grade NHL
- De novo
- Mature B-ALL
- Burkitt'S NHL
- Chemotherapy
- Rituximab
- Primary mediastinal diffuse large cell lymphoma
- B-precursor lymphoblastic lymphoma
- Burkitt Lymphoma
- Neoplasms
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Mediastinal Neoplasms
- Lymphoma, Large-Cell, Anaplastic